Argenica Therapeutics Ltd · ASX:AGN
Argenica Therapeutics — Investor Presentation (October 2024)
24 slides from Argenica Therapeutics's investor presentation, October 2024
Slide 1: Argenica Therapeutics Investor Presentation
ARGENICA THERAPEUTICS INVESTOR PRESENTATION ASX: AGN MANAGING DIRECTOR PRESENTATION OCTOBER 2024 1 www.argenica.com.au
Slide 2: Disclaimer
DISCLAIMER This presentation has been prepared by Argenica Therapeutics Limited and its related entities (the “Company”) and is not an offer document. It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company
Slide 3: Neuroprotection: The Therapeutic Opportunity
NEUROPROTECTION ARGENICA THERAPEUTICS THE THERAPEUTIC OPPORTUNITY 3 www.argenica.com.au
Slide 4: Breakthrough Neuroprotective Therapy
BREAKTHROUGH NEUROPROTECTIVE THERAPY ABOUT ARG-007 MISSION Commercialise a neuroprotective treatment that minimises brain damage and fosters recovery Cationic poly-arginine peptide following stroke & other neurological conditions ARGENICA THERAPEUTICS Multiple mechanisms of action working across mul
Slide 5: Our Lead Drug Candidate ARG-007
OUR LEAD DRUG CANDIDATE ARG-007 DISCOVERY PRE-CLINICAL PHASE 1 PHASE 2 PHASE 3 Efficacy Safety / Tox STROKE Damage to the brain from interruption of its blood supply SEVERE TBI ARGENICA THERAPEUTICS Trauma to the head or body causes a loss of consciousness HIE Hypoxic ischemic encephalopathy (HIE) d
Slide 6: Potential of ARG-007
POTENTIAL OF ARG-007 MAIN INDICATIONS ADDRESSABLE MARKET SUMMARY OF RESULTS TO DATE STROKE USD$12bn 66% reduction 70% reduction by 20301 in Brain Tissue Death 24 hours after stroke in Brain Tissue Death 28 Days after stroke 1. Coherent Market Insights Report – Acute Ischemic Stroke (AIS) Market Anal
Slide 7: Key Company Metrics
KEY COMPANY METRICS $15.9M $93.5M +$4M CASH @ BANK 1 MARKET CAP2 NON-DILUTIVE GRANTS 3 ARGENICA THERAPEUTICS 128.1M 37% SHARES HELD BY TOP 20 47% SHARES ON ISSUE PATIENTS ENROLLED IN PHASE 24 1. Cash balance as @ 30 June 2024 2. Calculated with closing price on @25th October 2024 being $0.75 7 3. Va
Slide 8: Stroke Recovery and ARG-007
ARGENICA THERAPEUTICS STROKE RECOVERY AND ARG-007 8 www.argenica.com.au
Slide 9: So Why Are We Targeting Stroke First?
SO WHY ARE WE TARGETING STROKE FIRST? INCIDENCE SOCIETAL IMPLICATIONS THE IMPORTANCE OF TIME ARGENICA THERAPEUTICS 45 SECONDS ONLY 10% 1.9 MILLION How often someone will recover almost brain cells are attacked each suffers an ischaemic completely, due to the extent minute during a stroke3 stroke in
Slide 10: Ischemic Stroke
ISCHEMIC STROKE EXAMPLE HOW ARG-007 WORKS IN STROKE ARGENICA THERAPEUTICS INITIAL INFARCTION SETS OFF A CASCADE OF CELL DEATH THAT WILL CONTINUE SPREADING FROM LOCATION ARG-007 STOPS THE CASCADE OF CELL DEATH & PROVIDES A PROTECTION BARRIER AROUND ITHE INITIAL INFARCTION 10 www.argenica.com.au ARG-0
Slide 11: Encouraging Stroke Results to Date
ENCOURAGING STROKE RESULTS TO DATE SUCCESSFUL PHASE 28 Days 1 (HUMAN after stroke in STUDY) PRECLINICAL & CLINICAL DATA preclinical model4 100% INDUCED Reduction in brain 90% STROKE cell death can make a significant difference SAFE TO 80% to patients’ outcome. ADMINISTER It could mean the IN THE FIE
Slide 12: Phase 2 Stroke Trial
ARGENICA THERAPEUTICS PHASE 2 STROKE TRIAL 12 www.argenica.com.au
Slide 13: Phase 2 Trial Design in Acute Ischaemic Stroke
PHASE 2 TRIAL DESIGN IN ACUTE ISCHAEMIC STROKE PATIENT HAS A PATIENT IN ARRIVES AT DIAGNOSE REHAB STROKE AMBULANCE HOSPITAL STROKE TYPE THROMBECTOMY BEGINS ARGENICA THERAPEUTICS Initial screening of Administration of Endpoints patients to meet inclusion 0.3mg/kg ARG-007 or Mortality rate and frequen
Slide 14: Example of What Phase 2 Trial Hopes to Achieve
EXAMPLE OF WHAT PHASE 2 TRIAL HOPES TO ACHIEVE: PROTECTING VULNERABLE BRAIN TISSUE (PENUMBRA) FOLLOWING STROKE & THROMBECTOMY Infarct core: permanent brain cell death Penumbra: Surrounding tissue ARGENICA THERAPEUTICS that is still alive but vulnerable ARG-007 aims to protect the vulnerable penumbra
Slide 15: Phase 2 Clinical Trial in Stroke
PHASE 2 CLINICAL TRIAL IN STROKE 10 Australian hospitals activated to recruit 92 ACTUAL PATIENT RECRUITMENT patients, currently 47% patients dosed1. Double-blinded, randomised, placebo- 100 controlled study with 0.3mg/kg dose of ARG- 90 007. ARGENICA THERAPEUTICS 80 70 ARG-007 given to patients that
Slide 16: Phase 2 Enrolment
PHASE 2 ENROLMENT 92 participants being enrolled across 10 stroke centres in Australia: ARGENICA THERAPEUTICS 16 www.argenica.com.au
Slide 17: The Opportunity for ARG-007 in Other Indications
THE OPPORTUNITY ARGENICA THERAPEUTICS FOR ARG-007 IN OTHER INDICATIONS 17 www.argenica.com.au
Slide 18: ARG-007 Potential in TBI – Rat Data
ARG-007 POTENTIAL IN TBI – RAT DATA ARG-007 SIGNIFICANTLY REDUCES NFH PROTEIN AND APP FOLLOWING TBI2 TRAUMATIC 2000 180 BRAIN 1800 160 51% INJURY 1600 52% reduction reduction 140 1400 ARGENICA THERAPEUTICS 120 Density of NFH (mm2) Density of APP (mm2) 1200 100 1000 Estimated USD$18.6bn 80 market siz
Slide 19: ARG-007 Potential in TBI – Ferret Data
ARG-007 POTENTIAL IN TBI – FERRET DATA ARG-007 SIGNIFICANTLY REDUCES AMYLOID PRECURSOR PROTEIN (APP) AND NEUROFILAMENT M-14.9 (RMO-14) & FOLLOWING TBI1 70% 51% 75% 64% reduction reduction ARGENICA THERAPEUTICS ARG-007 was found to protect brain cells in the injured brain by significantly reducing th
Slide 20: ARG-007 Potential in HIE
ARG-007 POTENTIAL IN HIE TOTAL BRAIN INJURY AT 4 WEEK POST HIE WITH ARG-007 TREATMENT OR ARG-007 WITH STANDARD OF CARE HYPOTHERMIA3 HYPOXIC-ISCHAEMIC ENCEPHALOPATHY (HIE) ARGENICA THERAPEUTICS HIE occurs in 1.5 to 2.5 births per 10001 Current standard of care is hypothermia Awarded A$2.5m grant to a
Slide 21: FDA Has Granted ODD & RPDD Status for HIE
FDA HAS GRANTED ODD & RPDD STATUS FOR HIE1 Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) status to ARG-007 for the treatment of Hypoxic Ischaemic Encephalopathy (HIE). ARGENICA THERAPEUTICS ODD qualifies AGN for incentives including: • Tax credits for qualified clinica
Slide 22: Near-Term Catalysts
NEAR-TERM CATALYSTS Each Quarter ARGENICA THERAPEUTICS • Phase 2 Trial Updates Q4 CY24 • Investigational New Drug Application to be submitted to the FDA Q2-Q4 CY25 • Phase 2 Dosing Complete • Release of Phase 2 Top Line Data Q3 CY24 – Q4 CY25 • Preclinical data for indications outside of stroke 22 w
Slide 23: Investment Highlights
3# NEAR-TERM CATALYSTS Several clinical and preclinical data points will be generated over the next 12 months, providing INVESTMENT significant upside to investors. HIGHLIGHTS ARGENICA THERAPEUTICS 1# SOLVING LARGE UNMET NEEDS 2# Nervous system disorders are the SIGNIFICANT PRE- 4# biggest cause of
Slide 24: Argenica Therapeutics
ARGENICA THERAPEUTICS For further information please contact: Dr Liz Dallimore CEO & Managing Director E: info@argenica.com.au 24 www.argenica.com.au
Argenica Therapeutics — Investor Presentation (October 2024) on 6ix